{"id":54935,"date":"2021-11-18T19:48:01","date_gmt":"2021-11-18T14:18:01","guid":{"rendered":"https:\/\/centralrecorder.com\/new-antibody-cocktail-shot-as-good-as-covid-jabs-at-protecting-people-with-weak-immune-systems\/"},"modified":"2021-11-18T19:49:06","modified_gmt":"2021-11-18T14:19:06","slug":"new-antibody-cocktail-shot-as-good-as-covid-jabs-at-protecting-people-with-weak-immune-systems","status":"publish","type":"post","link":"https:\/\/centralrecorder.com\/new-antibody-cocktail-shot-as-good-as-covid-jabs-at-protecting-people-with-weak-immune-systems\/","title":{"rendered":"New antibody cocktail shot ‘as good as Covid jabs\u2019 at protecting people with weak immune systems"},"content":{"rendered":"\n
\n

Trial data shows that a single antibody treatment is just as effective at stopping Covid, as evidenced by trial data.<\/p>\n

AstraZeneca has developed the jab to treat patients with weakened immune system who are often unable to respond to vaccinations.<\/p>\n

\n
\"The<\/a><\/p>\n

1<\/span><\/p>\n<\/div>

This new jab may help those with weakened immune systems that are unable to respond to vaccines.<\/span>Credit: Getty<\/span><\/figcaption><\/figure>\n

An analysis of more than 5,000 volunteers found the antibody cocktail \u2013 known as AZD7442 – offered 83 per cent protection over six months.<\/p>\n

None of the participants were given a Covid vaccination.<\/p>\n

Preventative treatment offers a real alternative for those who are at risk, such as patients with blood cancer or transplant recipients.<\/p>\n

Experts believe that around 2 percent of the population has a weak immune system. This is approximately 1 million Brits adults.<\/p>\n

In a separate study, patients receiving the drug within 3 days after falling ill with Covid had their symptoms reduced by 88 percent.<\/p>\n

The treatment is performed in one session, rather than two separate shots.<\/p>\n

AstraZeneca Executive Vice President Mene Pangalos said: \u201cThese new data add to the growing body of evidence supporting AZD7442’s potential.<\/p>\n

\u201cWe are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 as quickly as possible.”<\/p>\n

The treatment was more effective than double-vaccination in protecting against Covid illnesses over the long term, according to the results.<\/p>\n

Five months following the second injection, immunity drops to between 67% and 74%.<\/p>\n

Prof Penny Ward, Visiting Professor in Pharmaceutical Medicine at Kings College, London, said: \u201cThis antibody cocktail is, uniquely, capable of offering long lasting protection from Covid to patients that are immunosuppressed and may not have responded effectively to vaccination.<\/p>\n

\u201cIf may yet come to be considered an important adjunctive treatment for cancer patients and others needing immune suppressing therapy for other diseases.\u201d<\/p>\n

It’s too late for Plan B, as the European winter chill causes an increase in Covid cases and lockdowns<\/span><\/div>\n

<\/p>\n

\n

We will pay for your stories<\/h3>\n<\/p>\n
\n

Do you have a story to submit for the Central Recorder news desk<\/p>\n<\/div>\n<\/div>\n<\/div>\n